Here’s what you should know:
1. Takeda cleared every hurdle needed to acquire Shire. Shire’s shareholders voted Dec. 5 in an overwhelming majority to approve the deal, The Wall Street Journal reports.
2. While the deal will make Takeda one of the world’s most indebted shareholders, Takeda will also be among the world’s top 10 drugmakers.
3. Takeda announced its then $62 billion Shire acquisition in March. Over time, Takeda’s stock has fallen to value the deal at $58 billion, still the largest overseas acquisition by a Japanese company.
4. Takeda President and CEO Christophe Weber said, “With shareholder approval secured, we are looking forward to closing the acquisition in the coming weeks to create a more competitive, agile, highly profitable, and therefore more resilient company, poised to deliver highly innovative medicines and transformative care to patients around the world.”
More articles on gastroenterology:
29 statistics to know on physicians performing procedures, investing in ASCs
Court upholds sanctions against Louisiana surgery center physician — 5 insights
7 recent ASC acquisitions & partnerships — November 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
